Effect of anti-inflammatory bowel disease drug, E3040, on urate transport in rat renal brush border membrane vesicles

Eur J Pharmacol. 2000 Oct 6;406(1):45-8. doi: 10.1016/s0014-2999(00)00626-9.

Abstract

To confirm the assumption that 6-hydroxy-5, 7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole (E3040) acts on urate reabsorption by inhibiting urate-anion exchange at the luminal membrane of renal tubules, we investigated the inhibitory effect of E3040 and its two conjugated metabolites on hydroxyl ion (OH(-)) gradient-dependent urate uptake into brush border membrane vesicles from rat renal cortex and compared it with other uricosuric agents. The order of potency was AA193 (5-chloro-7, 8-dihydro-3-phenylfuro[2,3-g]-1,2-benzisoxazole-7-carboxylic acid)>benzbromarone>E3040>probenecid>E3040 sulfate>E3040 glucuronide. Furthermore, kinetic analysis revealed that E3040 may be a competitive inhibitor of the OH(-) gradient-dependent uptake of urate into brush border membrane vesicles.

MeSH terms

  • Animals
  • Benzothiazoles
  • Biological Transport / drug effects
  • Dose-Response Relationship, Drug
  • Gastrointestinal Agents / pharmacology*
  • Hydroxides / pharmacology
  • Kidney / drug effects*
  • Kidney / metabolism
  • Kinetics
  • Male
  • Microvilli / drug effects*
  • Microvilli / metabolism
  • Pyridines / pharmacology*
  • Rats
  • Rats, Wistar
  • Thiazoles / pharmacology*
  • Uric Acid / pharmacokinetics*
  • Uricosuric Agents / pharmacology

Substances

  • Benzothiazoles
  • Gastrointestinal Agents
  • Hydroxides
  • Pyridines
  • Thiazoles
  • Uricosuric Agents
  • E 3040
  • Uric Acid
  • hydroxide ion